- Report
- April 2025
- 175 Pages
Global
From €4086EUR$4,490USD£3,503GBP
- Report
- May 2024
- 129 Pages
Global
From €5915EUR$6,499USD£5,071GBP
- Report
- May 2024
- 138 Pages
Global
From €5915EUR$6,499USD£5,071GBP
- Report
- February 2024
- 110 Pages
Global
From €4323EUR$4,750USD£3,706GBP
- Report
- April 2021
- 191 Pages
Global
€20022EUR$22,000USD£17,165GBP
- Report
- August 2018
- 25 Pages
Global
From €9101EUR$10,000USD£7,802GBP
- Drug Pipelines
- January 2022
- 30 Pages
Global
From €455EUR$500USD£390GBP
Tarceva is a drug used to treat non-small cell lung cancer (NSCLC). It is a targeted therapy that works by blocking the epidermal growth factor receptor (EGFR) on the surface of cancer cells. This prevents the cancer cells from growing and spreading. Tarceva is used in combination with chemotherapy and other treatments to improve the effectiveness of the treatment. It is also used as a maintenance therapy to help keep the cancer from coming back. Tarceva is approved for use in the United States, Europe, and other countries.
Tarceva is a part of a larger market of drugs used to treat lung cancer. Other drugs in this market include chemotherapy drugs, immunotherapy drugs, and targeted therapies. These drugs are used in combination with each other to provide the best possible outcome for patients.
Companies in the Tarceva market include AstraZeneca, F. Hoffmann-La Roche, and Eli Lilly. Show Less Read more
